Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra<sup>®</sup>, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
<p>Abstract</p> <p>Background</p> <p>Ezatiostat hydrochloride liposomes for injection, a glutathione S-transferase P1-1 inhibitor, was evaluated in myelodysplastic syndrome (MDS). The objectives were to determine the safety, pharmacokinetics, and hematologic improvement...
Main Authors: | Burris Howard, Williams Stephanie, Emanuel Peter, Piro Lawrence, Ochoa Leonel, Callander Natalie, Galili Naomi, Raza Azra, Faderl Stefan, Estrov Zeev, Curtin Peter, Larson Richard A, Keck James G, Jones Marsha, Meng Lisa, Brown Gail L |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-05-01
|
Series: | Journal of Hematology & Oncology |
Online Access: | http://www.jhoonline.org/content/2/1/20 |
Similar Items
-
Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: A case report of sustained hematologic response following an abbreviated exposure
by: Quddus Fahd, et al.
Published: (2010-04-01) -
Oral ezatiostat HCl (Telintra<sup>®</sup>, TLK199) and Idiopathic Chronic Neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor
by: Lyons Roger M, et al.
Published: (2011-11-01) -
Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome
by: Galili, Naomi, et al.
Published: (2012) -
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
by: Raza Azra, et al.
Published: (2012-04-01) -
Scintigraphy with <sup>199</sup>Tl-chloride in diagnostics of nonspecific inflammatory diseases of small pelvis organs among women
by: A. P. Kurajov, et al.
Published: (2005-09-01)